SCHEMBL6804372

SCHEMBL6804372

Cc1ncc(-c2cccc(NC(=O)c3cccc4c3[nH]c3ccc(F)cc34)c2)n1C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 13/20 0.45
GSK3B P49841 10/20 0.42
IDO1 P14902 1/20 0.41
CLK2 P49760 1/20 0.40
CLK3 P49761 1/20 0.40
FGFR3 P22607 1/20 0.39
KDR P35968 1/20 0.39
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SCN4A P35499 1/20 0.38
SCN9A Q15858 1/20 0.38
SCN3A Q9NY46 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6803727 0.90 DYRK1A (0.46) DYRK1AGSK3BCLK2CLK3TP53
SCHEMBL6760168 0.90 DYRK1A (0.41) DYRK1AGSK3BIDO1CLK2CLK3
SCHEMBL6755618 0.89 DYRK1A (0.40) DYRK1AGSK3BTP53MAPTRAB9A
SCHEMBL6833169 0.83 DYRK1A (0.44) DYRK1AGSK3BCLK2CLK3FGFR3
SCHEMBL6805348 0.81 DYRK1A (0.43) DYRK1AGSK3BCLK2CLK3FGFR3
SCHEMBL6755637 0.80 MAPT (0.45) DYRK1AGSK3BTP53MAPTHTT
SCHEMBL6757933 0.80 SCN4A (0.42) DYRK1ATP53MAPTRAB9AKDM4E
SCHEMBL6760435 0.80 DYRK1A (0.45) DYRK1AGSK3BIDO1CLK2CLK3
SCHEMBL6756978 0.79 KMT2A (0.43) TP53MAPTHTTKDM4EMEN1
SCHEMBL6832909 0.78 RAB9A (0.42) TP53MAPTRAB9AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266774-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed
US-6770667-B1 N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-03 US disclosed
EP-1216240-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-06-26 EP disclosed
WO-2001025229-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266774-A1 Amide compounds TPH1, HTR1A, HTR5A DYRK1A 2942/4885GSK3B 2135/4885IDO1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.